{
  "abstract": "Background: Glucagon-like peptide-1 receptor agonists may influence systemic inflammation beyond their glucose-lowering effects, but direct comparative evidence against other incretin-based therapies remains limited.\n\nMethods: We conducted a retrospective active-comparator, new-user cohort study using routinely collected electronic health-record data from the Clinical Center of the University of Debrecen, Hungary. Patients with type 2 diabetes initiating a glucagon-like peptide-1 receptor agonist or a dipeptidyl peptidase-4 inhibitor between January 2001 and December 2024 after a 12-month washout were included. Baseline markers were summarized during months −12 to −1 and follow-up markers during months 4–12. The follow-up window was selected to reduce the influence of very early post-initiation testing while allowing assessment of a sustained biomarker difference. Propensity-score overlap weighting was used to balance demographic, metabolic, renal, cardiovascular, medication, and healthcare-observation characteristics.\n\nResults: The propensity-score cohort included 1,973 patients, including 1,322 glucagon-like peptide-1 receptor agonist and 651 dipeptidyl peptidase-4 inhibitor initiators; 838 had paired C-reactive protein measurements. The adjusted geometric mean ratio for follow-up C-reactive protein was 0.80 (95% confidence interval, 0.66–0.97; P = 0.024). The neutrophil-to-lymphocyte ratio was also lower (adjusted ratio, 0.92; 95% confidence interval, 0.87–0.97; P = 0.003; q=0.007), whereas platelet count was higher by 12.12×10 ⁹ /L (95% confidence interval, 4.65–19.59; P = 0.001; q=0.007). The C-reactive protein estimate remained similar after upper-tail winsorization, propensity-score re-estimation within the paired-CRP cohort, and patient-level bootstrap re-estimation of the propensity score. Restriction to patients with baseline CRP &lt;10 mg/L yielded a directionally similar but less precise estimate, whereas stabilized inverse-probability-of-treatment weighting did not statistically support the association.\n\nConclusion: GLP-1 receptor agonist initiation was associated with lower follow-up CRP and NLR than DPP-4 inhibitor initiation among patients with available paired measurements in the propensity-score overlap population. However, the CRP association was attenuated in the 12-month survivor-restricted analysis and varied across other sensitivity analyses. Residual confounding by adiposity, treatment-associated weight changes, and selection related to survival and laboratory availability limit causal interpretation. The findings should be considered exploratory comparative biomarker associations rather than evidence of a direct or weight-independent anti-inflammatory effect.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Epidemiology, Faculty of Health Sciences, University of Debrecen",
    "Division of Metabolic Diseases, Department of Internal Medicine, Faculty of Medicine, University of Debrecen"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 5,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Attila Nagy"
    },
    {
      "affs": [
        0
      ],
      "name": "Amr Sayed Ghanem"
    },
    {
      "affs": [
        0
      ],
      "name": "Battamir Ulambayar"
    },
    {
      "affs": [
        0
      ],
      "name": "Vivien Jendrek"
    },
    {
      "affs": [
        1
      ],
      "name": "Ferenc Sztanek"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/7dtzrb75m9wmd.bib",
  "cited_by": 0,
  "doi": "10.3389/fendo.2026.1959709",
  "fulltext_url": null,
  "id": "7dtzrb75m9wmd",
  "issns": [
    "1664-2392"
  ],
  "landing_url": "https://www.frontiersin.org/articles/10.3389/fendo.2026.1959709/full",
  "language": null,
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [],
  "openalex": null,
  "pdf_url": null,
  "pmcid": null,
  "pmid": null,
  "published": "2026-11-16",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/7dtzrb75m9wmd.ris",
  "sources": [
    {
      "first_seen": "2026-11-16T12:26:02Z",
      "native_id": "10.3389/fendo.2026.1959709",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fendo.2026.1959709/full"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "issn:1664-2392",
      "subfield": "endocrinology-metabolism"
    }
  ],
  "title": "Systemic inflammatory markers after GLP-1 receptor agonist versus DPP-4 inhibitor initiation in type 2 diabetes: an overlap-weighted active-comparator cohort study",
  "title_text": "Systemic inflammatory markers after GLP-1 receptor agonist versus DPP-4 inhibitor initiation in type 2 diabetes: an overlap-weighted active-comparator cohort study",
  "type": "peer-reviewed",
  "updated_at": "2026-11-16T12:26:02Z",
  "url": "https://research.draconitic.com/paper/7dtzrb75m9wmd",
  "venue": "Frontiers in Endocrinology",
  "versions": []
}